{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:51:11Z","timestamp":1772139071559,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.leukres.2009.04.006","type":"journal-article","created":{"date-parts":[[2009,9,18]],"date-time":"2009-09-18T09:38:49Z","timestamp":1253266729000},"page":"1615-1618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience"],"prefix":"10.1016","volume":"33","author":[{"given":"Weiyan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingkui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maofang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.04.006_bib1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.04.006_bib2","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.006_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2009.04.006_bib4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.04.006_bib5","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeuticagents","volume":"9","author":"Ma","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.04.006_bib6","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiplemyeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2009.04.006_bib7","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.04.006_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2009.04.006_bib9","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.04.006_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.leu.2404459","article-title":"Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion","volume":"21","author":"Sagaster","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2009.04.006_bib11","first-page":"929","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone","volume":"91","author":"Jagannath","year":"2006","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.leukres.2009.04.006_bib12","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.leukres.2009.04.006_bib13","first-page":"653","article-title":"Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma","volume":"27","author":"Yuan","year":"2006","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"10.1016\/j.leukres.2009.04.006_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/10245330701214236","article-title":"Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma","volume":"12","author":"Wang","year":"2007","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.leukres.2009.04.006_bib15","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.006_bib16","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.04.006_bib17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2009.04.006_bib18","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria version 2.0. http:\/\/ctep.cancer.gov\/forms\/ctcv2nom-4-30-99-final3.pdf."},{"issue":"6","key":"10.1016\/j.leukres.2009.04.006_bib19","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2009.04.006_bib20","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2009.04.006_bib21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","article-title":"Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"24","author":"Berenson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.leukres.2009.04.006_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2004.11.004","article-title":"Bortezomib in combination with dexamethasone for relapsed multiple myeloma","volume":"29","author":"Kropff","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2009.04.006_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3816\/CLM.2006.n.047","article-title":"Response to bortezomib and activation of osteoblasts in multiple myeloma","volume":"7","author":"Zangari","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.leukres.2009.04.006_bib24","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609001805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609001805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:56:23Z","timestamp":1758934583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609001805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0145212609001805"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.04.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2009.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}